Aekn.de - Startseite - ÄKN - Ärztekammer Niedersachsen
Provided by Alexa ranking,
aekn.de has ranked
N/A in
N/A and
2,012,639 on the world.
aekn.de reaches roughly
1,548 users per day and delivers about
46,426 users each month. The domain aekn.de uses a Commercial suffix and it's server(s) are located in
N/A with the IP number
185.243.133.184 and it is a
.de domain.
WEB4 days ago · Die ÄKN bietet die Weiterbildung am 31. Mai 2024 in der Zeit von 9 bis 16.30 Uhr im Ärztehaus in Hannover an. > PDF ansehen. ÄKN Aktuell. Online-Fortbildung „Alkohol nüchtern betrachtet: Ärztinnen und Ärzte …
List of domain same IP 185.243.133.184
Search Results related to aekn.de on Search Engine
-
Startseite - ÄKN - Ärztekammer Niedersachsen
https://www.aekn.de/
WEB4 days ago · Die ÄKN bietet die Weiterbildung am 31. Mai 2024 in der Zeit von 9 bis 16.30 Uhr im Ärztehaus in Hannover an. > PDF ansehen. ÄKN Aktuell. Online-Fortbildung „Alkohol nüchtern betrachtet: Ärztinnen und Ärzte …
DA: 10 PA: 98 MOZ Rank: 80
-
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI …
https://www.biospace.com/article/releases/alvotech-and-teva-announce-u-s-fda-approval-of-selarsdi-ustekinumab-aekn-biosimilar-to-stelara-ustekinumab-/
WEB2 days ago · INDICATIONS FOR SELARSDI (ustekinumab-aekn) SELARSDI™ (ustekinumab-aekn) Injection, is a human interleukin-12 and -23 antagonist indicated for: the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
DA: 90 PA: 85 MOZ Rank: 34
-
FDA Approves Second Ustekinumab Biosimilar - Medscape
https://www.medscape.com/viewarticle/fda-approves-second-ustekinumab-biosimilar-2024a10007ge
WEB2 days ago · April 17, 2024. 0. The US Food and Drug Administration (FDA) has approved the biosimilar ustekinumab-aekn (Selarsdi) for the treatment of moderate to severe plaque psoriasis and psoriatic ...
DA: 17 PA: 42 MOZ Rank: 32
-
Ustekinumab Biosimilar Selarsdi Gets FDA Approval - MPR
https://www.empr.com/home/news/generics-news/ustekinumab-biosimilar-selarsdi-gets-fda-approval/
WEB2 days ago · April 17, 2024. The product is expected to be available in February 2025. The Food and Drug Administration (FDA) has approved Selarsdi ™ (ustekinumab-aekn), a biosimilar to Stelara ...
DA: 22 PA: 60 MOZ Rank: 19
-
FDA Approves Selarsdi (ustekinumab-aekn), a Biosimilar to Stelara
https://www.drugs.com/newdrugs/fda-approves-selarsdi-ustekinumab-aekn-biosimilar-stelara-6247.html
WEB4 days ago · Selarsdi is the second biosimilar approved under the strategic partnership: in February 2024, the FDA approved SIMLANDI®, the first high-concentration, citrate-free biosimilar to Humira that has been granted an interchangeability status by the FDA. The FDA approval of Selarsdi, referred to as AVT04 during development, was based on a …
DA: 44 PA: 46 MOZ Rank: 99
-
Weiterbildung - ÄKN - Ärztekammer Niedersachsen - aekn.de
https://www.aekn.de/aerzte/weiterbildung
WEBÄrzte. Weiterbildung. Die Abteilung Aus-, Fort- und Weiterbildung der Ärztekammer Niedersachsen. ermächtigt Ärztinnen und Ärzte auf Antrag zur ärztlichen Weiterbildung und erteilt Stätten die Zulassung, prüft die regelgerechte Absolvierung der Weiterbildung und.
DA: 63 PA: 54 MOZ Rank: 95
-
FDA Approves Biosimilar Ustekinumab-aekn for PsO, PsA
https://www.hcplive.com/view/fda-approves-ustekinumab-aekn-for-pso-psa
WEB3 days ago · Lana Pine. Alvotech and Teva announced the US Food and Drug Administration (FDA) approval of its ustekinumab (Stelara) biosimilar, ustekinumab-aekn (Selardsi), for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis (PsA) in both adults and pediatric patients aged ≥ 6 years. 1. “The approval of …
DA: 48 PA: 57 MOZ Rank: 86
-
Ärztekammer Niedersachsen - YouTube
https://www.youtube.com/ärztekammerniedersachsen
WEBÄrztekammer Niedersachsen. @ArztekammerNiedersachsen • 2.5K subscribers • 130 videos. ÄKN-TV ist der Informationskanal der Ärztekammer Niedersachsen (ÄKN). Hier finden Sie Informationen und...
DA: 60 PA: 65 MOZ Rank: 16
-
Teva, Alvotech Secure FDA Approval for Stelara Biosimilar
https://www.biospace.com/article/teva-alvotech-secure-fda-approval-for-stelara-biosimilar-with-early-2025-launch/
WEB1 day ago · The FDA on Tuesday approved Alvotech and Teva Pharmaceuticals ’ Selarsdi (astekinumab-aekn), a biosimilar to Johnson & Johnson ’s blockbuster immunotherapy Stelara (ustekinumab). Like its branded reference product, Selarsdi is a subcutaneous injection that can be used to treat moderate-to-severe plaque psoriasis and active …
DA: 97 PA: 3 MOZ Rank: 19
-
Willkommen - Serviceportal
https://portal.aekn.de/
WEBWillkommen im Mitgliederportal der Ärztekammer Niedersachsen. Nutzen Sie die Vorteile der Onlineangebote der äkn. Um dieses Mitgliederportal nutzen zu können, müssen Sie …
DA: 42 PA: 49 MOZ Rank: 14
Alexa Rank
GLOBAL RANK
Alexa Reach
Page length
Alexa Rank Country N/A
Daily Unique Visitors
Monthly Unique Visitors
Vistor via Country
Country lang
Country code
Total visitor
Country
Country code
Total visitor
Alexa Traffic Graph
Alexa daily traffic trend graph
Alexa daily pageviews (percent) graph
Alexa daily pageviews per user graph
Alexa time on site (in minutes) graph
Alexa bounce rate (percent) graph
Alexa search visits graph
SEOquake Zone
| Title |
|
|
Tips |
| Description |
|
|
Tips |
| Keywords |
|
|
Tips |
| Viewport |
|
|
Tips |
| Icon |
|
|
|
| UTF-8 |
|
|
|
Mini site formation by Alexa Rank
DNS Record
| Host |
Type |
Class |
TTL |
Extra |
| aekn.de |
SOA |
IN |
3600 |
Mname: ns.htp-tel.de
Rname: hostmaster.htp.net
Serial: 2024041900
Refresh: 43200
Retry: 7200
Expire: 1209600
Minimum-ttl: 3600
|
| aekn.de |
NS |
IN |
3600 |
Target: ns.htp-tel.de
|
| aekn.de |
NS |
IN |
3600 |
Target: ns2.htp-tel.de
|
| aekn.de |
NS |
IN |
3600 |
Target: ns1.htp-tel.de
|
| aekn.de |
TXT |
IN |
3600 |
Txt: apple-domain-verification=LheiMrsvIWy2YnKn
Entries_0: apple-domain-verification=LheiMrsvIWy2YnKn
|
| aekn.de |
TXT |
IN |
3600 |
Txt: cisco-ci-domain-verification=20c1d45735e4dd34de264ee35a3888f5136d05d5d1ecf3103c07a305659ebb85
Entries_0: cisco-ci-domain-verification=20c1d45735e4dd34de264ee35a3888f5136d05d5d1ecf3103c07a305659ebb85
|
| aekn.de |
TXT |
IN |
3600 |
Txt: v=spf1 ip4:81.14.210.111/32 -all
Entries_0: v=spf1 ip4:81.14.210.111/32 -all
|
| aekn.de |
MX |
IN |
3600 |
Pri: 100
Target: mail.aekn.de
|
| aekn.de |
A |
IN |
3600 |
Ip: 185.243.133.184
|
Hosting and Whois Zone
| IP |
185.243.133.184 |
| Domain infomation |
% Restricted rights.
%
% Terms and Conditions of Use
%
% The above data may only be used within the scope of technical or
% administrative necessities of Internet operation or to remedy legal
% problems.
% The use for other purposes, in particular for advertising, is not permitted.
%
% The DENIC whois service on port 43 doesn't disclose any information concerning
% the domain holder, general request and abuse contact.
% This information can be obtained through use of our web-based whois service
% available at the DENIC website:
% http://www.denic.de/en/domains/whois-service/web-whois.html
%
%
Domain: aekn.de
Nserver: ns1.htp-tel.de
Nserver: ns2.htp-tel.de
Nserver: ns.htp-tel.de
Status: connect
Changed: 2011-11-25T11:53:08+01:00
|
